Viibryd may be associated with acute pancreatitis, a condition that can increase a person’s risk for pancreatic cancer. Filing a Viibryd lawsuit could be an option for individuals who were diagnosed with either condition following treatment with this antidepressant medication.
The nationwide law firm of Bernstein Liebhard LLP is investigating potential legal claims involving Viibryd and acute pancreatitis, as well as pancreatic cancer. To learn more about filing a Viibryd lawsuit, please call (888) 994-5118.
Approved in 2011, Viibryd is the first and only Selective Serotonin Reuptake Inhibitor (SSRI) and 5HT1a receptor partial agonist approved to treat adults suffering from major depressive disorder, or MDD. No one is really sure how Viibryd works. SSRI antidepressants are thought to affect levels of serotonin, a neurotransmitter in the brain that may affect mood. However, the role of 5HT1A partial agonist activity on serotonergic transmission and antidepressant effect is unknown.
In September 2016, the U.S. Food & Drug Administration (FDA) posted a letter to Forest Laboratories on its website indicating that it was seeking changes to the Viibryd label relating to, among other things, acute pancreatitis:
“We also refer to our Safety Labeling Change Notification letters dated May 31, 2016, and June 8, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Viibryd (vilazodone). This information pertains to the risk of sleep paralysis and acute pancreatitis,” the letter stated.
“This supplemental new drug application provides for the addition of sleep paralysis and acute pancreatitis to the Post-marketing Experience subsection (6.2) consistent with our May 31, 2016, and June 8, 2016 letters.”
Acute pancreatitis occurs when the pancreas suddenly becomes inflamed. The condition usually results in hospitalization, and is fatal about 10% of the time. Victims of acute pancreatitis endure severe pain, and even malnutrition. As many as 25% of patients who develop acute pancreatitis will experience a recurrent episode within the first several years. Acute pancreatitis, especially if it recurs, greatly increases an individual’s risk of pancreatic cancer, one of the deadliest forms of cancer.
Viibryd patients who suffer acute pancreatitis or pancreatic cancer will likely incur significant physical, financial and emotional damages due to their illness. The same can be said of their family members should the illness result in death. While no amount of money can make up for this kind of suffering, filing a Viibryd lawsuit can help alleged victims recover some of these damages, including compensation for:
Bernstein Liebhard LLP is offering free Viibryd lawsuit reviews to individuals who may have been harmed by this medication. Please call (888) 994-5118 to arrange for your legal consultation today.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.